Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Heron Therapeutics initiates phase Ib/II study of HTX-034 for postoperative pain

May 19, 2020

Intra-Cellular Therapies patents PDE2A inhibitors

May 18, 2020

Microbiome modulates effects of ALS mutation

May 18, 2020

Phase IIb study of PTI-125 in Alzheimer's disease does not meet primary endpoint

May 18, 2020

New kappa opioid receptor agonists synthesized at Nippon Chemiphar

May 15, 2020

Improved therapeutic index could reduce opioid toxicity

May 14, 2020

Enrollment of first patient in phase III study of viltolarsen in boys with DMD

May 14, 2020

Sunovion discontinues development of dasotraline

May 14, 2020

Discovery of potent BACE1 inhibitor, AM-6494

May 14, 2020

New biomarker identified for the aging brain

May 13, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...